

[RESILIENCE

“BUSINESS AS USUAL”?

Only if you're satisfied with results as usual.

Biomanufacturing for:

- Biologics
- Vaccines
- Nucleic Acids
- Cell Therapy
- Gene Therapy

[RESILIENCE

“BUSINESS AS USUAL”?

Only if you're satisfied with results as usual.

Biomanufacturing for:

- Biologics
- Vaccines
- Nucleic Acids
- Cell Therapy
- Gene Therapy

- [Magazine](#)
 - [Current / Back Issue](#)
 - [Features](#)
 - [Editorial](#)
 - [Columns](#)
 - [Editorial Guidelines](#)
 - [Subscribe Now](#)
 - [Advertise Now](#)
 - [Enewsletter Archive](#)
 - [Digital Edition](#)
- [Directory](#)
 - [Companies](#)
 - [Categories](#)
 - [Corporate Capabilities](#)
 - [Add Your Company](#)
- [Manufacturing](#)
 - [APIs](#)
 - [Aseptic Processing](#)
 - [Cleaning Validation](#)
 - [Clinical Trial Materials](#)
 - [Cytotoxics and High Potency Manufacturing](#)
 - [Equipment](#)
 - [Excipients](#)
 - [Extractables and Leachables](#)
 - [Facilities](#)
 - [Fill/Finish](#)
 - [Lyophilization](#)
 - [Parenterals](#)
 - [Process Development](#)
 - [Process Validation](#)
 - [Risk Management](#)
 - [Scale-up/ Technology Transfer](#)
 - [Solid Dosage/ Creams/ Ointments](#)
 - [cGMP Manufacture](#)
- [Packaging](#)
 - [Capsules](#)
 - [Cold Chain Management](#)
 - [Injectables](#)
 - [Logistics](#)
 - [Serialization](#)
 - [Solid Dosage / Semi-solids](#)
 - [Supply Chain](#)
 - [Vials](#)
- [Development](#)
 - [Analytical Services](#)
 - [Bioanalytical Services](#)
 - [Bioassay Development](#)
 - [Biologics, Proteins, Vaccines](#)
 - [Biosimilars](#)
 - [Chemistry](#)
 - [Clinical Trials](#)
 - [Drug Delivery](#)
 - [Drug Development](#)
 - [Drug Discovery](#)
 - [Formulation Development](#)
 - [Information Technology](#)
 - [Laboratory Testing](#)
 - [Methods Development](#)
 - [Microbiology](#)
 - [Preclinical Outsourcing](#)
 - [R&D](#)
 - [Toxicology](#)
- [Compliance](#)
 - [Filtration & Purification](#)
 - [GMPs/GCPs](#)
 - [Inspections](#)
 - [QA/QC](#)
 - [Regulatory Affairs](#)
 - [Validation](#)
- [Top 25 Pharma & BioPharma](#)
- [Contract Pharma Direct](#)
- [Breaking News](#)
- [Online Exclusives](#)
- [Slideshows](#)
- [Experts Opinions](#)
- [Surveys](#)
 - [Outsourcing Survey](#)
 - [Salary Survey](#)
- [Glossary](#)
- [Videos](#)
- [White Papers](#)
- [Podcasts](#)
- [Infographics](#)
- [Microsites](#)
 - [Companies](#)
 - [News Releases](#)
 - [Posters](#)
 - [Brochures](#)


- [Services](#)
- [Videos](#)
- [Case Study](#)
- [White Papers](#)
- [Contract Pharma Conference](#)
 - [Contract Pharma Conference](#)
 - [Speakers](#)
 - [Exhibitors](#)
 - [Conference Sessions](#)
- [eBook](#)
- [Webinars](#)
- [Events](#)
 - [Industry Events](#)
 - [Live from Show Events](#)
 - [Webinars](#)
- [Classifieds / Job Bank](#)
 - [Classifieds](#)
 - [Job Bank](#)
- [About Us](#)
 - [About Us](#)
 - [Contact Us](#)
 - [Advertise With Us](#)
 - [Privacy Policy](#)
 - [Terms of Use](#)

Features

Early-Stage Biotech: What's Essential and What's Not

Using contract services to "balance" the capabilities needed now and those that will prepare for the future.



 Jonathan Horn, Bob Johnson & Scott Myers, Tunnell Consulting02.06.23

You are a CxO at an early-stage BioPharma company. You have succeeded in obtaining your first round of funding, and those investors and your small team are excited about the prospects of your unique therapy for patient outcomes. That said, you are losing sleep each night. As you toss and turn, three key questions seem to haunt you:



1. How do I get into the clinic?
2. How do I get the right people for our team?
3. How do I meet milestones to keep raising funds?

Even as you grasp at potential answers to these questions, sleep continues to elude you as you realize that the questions are interrelated; answers to one seem to depend on the answers to others. And on it goes, late into the night.



Here at Tunnell, we have found that successful early-stage BioPharmas institute required capabilities to address the three questions above by focusing on the following:

- Creating an integrated development program roadmap
- Utilizing flexible staffing and recruiting models
- Executing detailed plans that follow the roadmap

BioPharmas may avoid operational problems and unnecessary costs by balancing between the capabilities needed now and those that will prepare the company appropriately for the future. This balance can be attained via "fit-for-purpose" investments now, enabled by the use of a contract services approach.

Why Fit-for-Purpose? Early-stage BioPharmas often fall behind on building required capabilities due to:

- Lack of time or resources dedicated to planning and instituting such capabilities
- A focus on the science/technology, versus the regulatory and operations aspects that must be addressed
- Prematurely allocating limited funding given the inherent risks in drug development of assets progressing through from pre-clinical to clinical to market
- A desire to keep their entities attractive to potential investors and/or buyers by avoiding over-investment and overhead

The catch-22 here is that the factors listed above that make companies hesitant to build capabilities, are also critical factors that must be addressed so that companies can meet the milestones that are so important to attract additional investment and continued development. Companies can navigate the delicate balancing act by instituting "must-have" (fit-for-purpose) capabilities, avoiding investing precious funds when not needed.

But the question remains. How to achieve this without critical internal staff? An approach is to utilize contract services.

What are Contract Services? Early-stage BioPharmas are familiar with contracting in areas such as research, development, testing, and manufacturing. For example, they will likely contract with an external contract research organization (CRO) to provide biopharmaceutical development, biologic assay development, pre-clinical studies, and eventually clinical trials management. But why restrict such an approach to areas such as research, development, testing, and manufacturing?

Often, early-stage BioPharmas need to complete projects in other areas (quality, development program management, and regulatory for example) but lack the internal resources to complete such work. We have found the contract services approach can be valuable in these areas. Unlike traditional consulting projects—where combined teams of clients and consultants work together—contract services work is primarily completed by external resources. And unlike outsourcing—where a function or service is provided externally for an extended duration—the goal is to transition the function or service in-house over time if and when the early-stage BioPharma meets milestones that warrant such a move. In this way, the company can be positioned to grow and further invest without making undue investments prematurely.

Another unique and valuable aspect of contract services is that unlike simply hiring separate independent contractors, contract services are executed by a single provider, with a single project management structure, methodology, and often pre-developed materials to hasten the process. **Start with a**

Development Program Roadmap The development program should provide a roadmap for getting from the lab and pre-clinical to IND submission and phase one clinical studies. Clinical, regulatory, quality, and manufacturing components are required in such a roadmap. Companies can start by addressing Investigational New Drug (IND) readiness, identifying gaps, and developing a remediation plan to address those gaps. The remediation plan provides a baseline for documenting the pathway to IND submission and phase one. It is important to evaluate pathway options, and to develop detailed plans with resource requirements, timings, and costs. **Utilize Flexible Staffing and Recruiting Models** The development program roadmap provides a guide for executing

tasks. To minimize over-investment, the resource requirements specified in the roadmap can be filled utilizing contract services. This is especially valuable given the tight labor market and ever-increasing demand for life sciences experts. A contract services provider should have an organized approach to sourcing experts. This should include a multi-step screening process, dedicated recruiting team, and a database of experts managed by a talent acquisition system.

Three types of resources are typically needed by an early-stage BioPharma:

- Interim Leaders / Executives / Managers
- Management Direct Hires
- Subject Matter Experts (SMEs) in Development, Quality, CMC Processes, Pre-Clinical, and Regulatory

Those resources can be provided in multiple ways, including:

- Full-time contract staffing
- Direct hires via retained searches and/or contract-to-hire)
- Fractional advisory roles ("on-demand" advisors on retainer)

Although people will be working in a virtual environment—and will come from different companies—roles and responsibilities must be specified and communicated to instill clarity regarding mission, working relationships, and culture. **Execute Detailed Plans That Follow the Roadmap** The development program provides a roadmap and guide to key work activities, milestones, and resource requirements. And with a flexible staffing model, the organization now has access to resources. So now, it comes down to execution. Examples of three key areas which must be executed by an early-stage BioPharma, and that can be provided via a contract services approach, include:

- Regulatory approval mapping
- CRO/CDMO selection
- Quality Management System (QMS) implementation

These three areas are inseparably interrelated. A regulatory strategy must be mapped out so that the company knows the key milestones/criteria it must meet, and its plans for doing so. A QMS supports that strategy by defining the process and capturing the data required to maintain compliance, while also spelling out quality requirements, corrective actions when quality falls short, and the results of remediations. And since the company is virtual, both QMS and regulatory must provide oversight with the CRO/CDMO that has been selected. As such, all three of these components should be instituted by an early-stage BioPharma in a coordinated fashion and not separately.

The ultimate goal is to drive towards Phase one clinical material manufacture and improved probability of a successful IND filing. This requires:

- Additional detailed planning across clinical, regulatory, quality, and manufacturing
- Ongoing program/project management
- Supplier/material identification and qualification
- Selection and coordination of contract organizations

• Process and analytical development document creation and review **Regulatory Approval Mapping** Defining specific regulatory needs—and developing a regulatory map to follow—begins with a gap assessment. Using a contract services approach, pre-developed regulatory map templates and gap analysis checklists can be used to assess and understand the early-stage BioPharma's needs across product development stages such as:

- Regulatory strategy development
- Regulatory guidance
- Authoring and reviews of study reports
- Preparation for Pre-IND meetings
- Authoring and reviews of regulatory filings
- Clinical trial design

Using a contract services approach, resources can be provided to address gaps. Note that regulatory activities have inevitable peaks and valleys in workload; an "on-demand" fractional advisory approach is often helpful to manage such a work environment.

CRO/CDMO Selection Engaging a CRO and/or CDMO requires an organized process that can be executed by a contract services approach. A methodology for selecting and instituting such relationships typically has four main components:

- Defining the timeline, based on the stage of drug development and geographic approval submission requirements
- Determining the capabilities required, technical and business requirements (including geographic requirements and supply chain logistics) and cultural alignment needed
- Issuing a Request for Information (RFI) and/or a Request for Proposal (RFP)

- Selecting a CRO and/or CDMO, finalizing service agreements and instituting operations

Key value-adds that a contract services approach can provide include pre-screened lists of CROs and CDMOs, RFI/RFP templates, execution of the selection process, and the provision of staff to manage the CRO and CDMO relationships. **Quality Management System** Whether a company is 100% virtual or not, quality management system documentation is typically required across the following areas:

- Quality Management
- Production
- Facilities/Equipment
- Laboratory
- Supply Chain / Materials Management
- Information Technology
- Pharmacovigilance

In a contract services approach, templates can be provided to an early-stage BioPharma (and, as needed, subject matter experts to tailor the templates). The templates should be organized in a library based on a QMS procedure hierarchy (policies, SOPs, work instructions) so that redundancy is minimized and gaps are eliminated. We have found that this significantly reduces time for initial GMP-readiness for emerging companies.

Key value-adds that a contract services approach can provide include pre-written templates, alignment with the quality system in place, and ensuring that SOPs are appropriately written for a virtual company with multiple business partners, as opposed to a traditional "Big Pharma" model where most if not all functions are in-house.

Summing It All Up The following statistic is common knowledge in the life sciences industry: only one out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. And there is a myriad of different estimates regarding the failure rate of early-stage BioPharma companies. Wading through all those statistics, what is clear is that the odds of success are not favorable. Those odds do increase when an early-stage BioPharma continues to meet milestones and secure investments from Big Pharma. Studies show that success rates double when Big Pharma takes an investment position in a BioPharma startup.

Although many companies fail due to problems with their product, others fail because they are not able to strike a balance between investments required to meet milestones and secure needed funding vs. over-investing prematurely. In situations where the science is solid, the result is not only the loss of a promising therapy and the loss of potential returns on investment, but also the continued loss of sleep for the leaders of those organizations who continue to wonder "what if."

Bob Johnson is group vice president at Tunnell Consulting, a management consulting firm dedicated to solving complex problems for life sciences companies and government agencies. He can be reached at bob.johnson@tunnellconsulting.com.

Jonathan Horn is a principal at Tunnell Consulting and has over 30 years of management consulting expertise in the areas of assessing, designing, and managing enterprise transformation initiatives. He can be reached at jonathan.horn@tunnellconsulting.com.

Scott Meyers is a principal at Tunnell Consulting and has more than 25 years of experience in technical, managerial, and business leadership in the global pharmaceutical industry. He can be reached at scott.meyers@tunnellconsulting.com.

COMPANY SPOTLIGHT: BioIVT

BioIVT is a leading global provider of high-quality biological specimens and value-added services to the life science industry.

[Learn More >>](#)



Related Searches

- [Biologics, Proteins, Vaccines](#)
- [Drug Development](#)
- [Bioanalytical Services](#)



august
bioservices

Sterile Injectables CDMO
US-Based • End-to-End • All Under One Roof
2023/2024 capacity available!

- o

- o [Leadership Spotlight: Thomas Otto & Peter Soelkner](#)

Vetter's managing directors share business insights and talk CDMO industry trends.
Tim Wright, Editor 09.07.22



- o [Regulatory Affairs](#)
[Responding to Consumer Complaints While Working with CMOs](#)

Whether their products are pharmaceuticals, medical devices or combination products, manufacturers face questions about how to respond to consumer complaints.

Ricki Chase & Carrie Colella, Lachman Consultants
09.07.22



- o [Logistics](#) | [Supply Chain](#)



[Future Pandemic Preparedness](#)

The lessons COVID-19 has taught us and the way forward to protect global public health.
Rich Quelch, Global Head of Marketing, Origin 09.07.22

Scaling Up ADC Payloads

Learn more about the scale up of antibody drug conjugates payloads by viewing this webinar.

Released by [Lonza](#)





- o [Biologics, Proteins, Vaccines](#)
[Cell and Gene Therapy Contract Manufacturers Are Critical to Industry Success](#)

CDMOs hold the key to lack of industry capacity, hiring challenges.
Joel Ranck, Market Analyst 09.07.22

- [Aseptic Processing](#) | [Fill/Finish](#) | [Lyophilization](#) | [Parenterals](#)
[Why Robotic Sterile Fill-Finish Is Key for Speed to Clinic and Patient Safety](#)

Sterile fill-finish is a mainstay in pharmaceutical manufacturing and robotic platforms will be a true differentiator.

Mark Shepanski, PCI Pharma Services 09.07.22



- [Aseptic Processing](#) | [Fill/Finish](#) | [Lyophilization](#) | [Parenterals](#)



[Aseptic Manufacturing: Key Trends, Challenges and the Importance of the Right CDMO Partner](#)

Key considerations for successful aseptic manufacturing and lyophilization.

Igor Nikoulin and Miray Mousa, Societal CDMO 09.07.22

COMPANY SPOTLIGHT: Federal Equipment Company

Federal Equipment Company is a top supplier of used pharmaceutical equipment and the trusted name in the processing-equipment industry, stocking thousands of ready-to-ship pieces of equipment.

[Learn More >>](#)



- [Biotechnology's Role in Improving Stroke Outcomes](#)


The biotechnology sector is investigating the role of neural plasticity to treat the damage caused by stroke.

Paul Brennan, President and CEO, NervGen Pharma Corp. 07.11.22

- [CEO Spotlight: Marc Kikuchi](#)

A conversation with the Chief Executive Officer of Dr. Reddy's Laboratories' North American Generics business.

Tim Wright, Editor 07.11.22



- [Cold Chain Management](#) | [Facilities](#) | [Logistics](#) | [Supply Chain](#)
[Newsmakers: Darren Shirley](#)

A Q&A with the president of Apace Packaging and the founder and president of R&S Solutions / Direct Customer Solutions.

Tim Wright, Editor 06.07.22



COMPANY SPOTLIGHT: Adare Pharma Solutions

We are a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms.

[Learn More >>](#)



- [Serialization](#)
[Are You Prepared for the 2023 DSCSA Deadline?](#)

From updating processes to identifying security gaps, the time to prepare for the Nov. 27, 2023 deadline is now.

Gina Parry, Distribution & Pharmaceutical Sales Manager, VAI 06.07.22

- [R&D](#)
[Rethinking the Changing Role of the CRO](#)

Addressing the disruptors driving transformational change.

John Wilson, Senior Vice President and General Manager, Life Sciences, physIQ, Tammy D'Lugin-Monroe, RN, MA, Vice President, Therapeutic Strategy and Innovation, General Medicine, Syneos Health® 06.07.22



- [23rd Annual Salary Survey](#)

The results from Contract Pharma's annual salary survey are in!
06.07.22



COMPANY SPOTLIGHT: Vetter

Vetter's full portfolio of services includes dedicated resources for both clinical development and commercial manufacturing.

[Learn More >>](#)



- [Information Technology](#) | [Scale-up/Technology Transfer](#)
Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
 Putting Pharma 4.0 principles into practice, and how a crucial foundation for doing so is the digitation of technology transfer in the life sciences enterprise.
 Sachin Misra, Principal Global Leader - Life Sciences, Kalypso 06.07.22



- CEO Spotlight: David Chang**
 WuXi Advanced Therapies' chief executive talks trends, company highlights and the future of cell and gene therapies.
 Tim Wright, Editor, Contract Pharma 06.07.22



- [Biologics, Proteins, Vaccines](#)



[Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing](#)

Single-use systems are cost-effective and produce high-quality pharmaceuticals, but they come with challenges inherent in using plastic materials.
 Sandi Schaible, Senior Director of Analytical Chemistry, WuXi AppTec 06.07.22

- [R&D](#)
CRO Industry Market Report
 M&A, investments in capabilities, technology trends and regulatory frameworks for clinical trials today.
 Kristin Brooks, Managing Editor, Contract Pharma 06.07.22



- [Biologics, Proteins, Vaccines](#) | [R&D](#)
SARS-CoV-2 R&D: Is It Over?
 With so much time and resources focused on SARS-CoV-2 R&D, will the pharmaceutical industry need to pivot their focus once again?
 Luc Gagnon, Vice President of Vaccine Sciences, Nexelis 05.02.22



- [cGMP Manufacture](#) | [GMPs/GCPs](#)



[Sustainability: A New Threat or Opportunity for CDMOs?](#)

CDMOs must be proactive in adapting to the sustainability standards of pharma companies.
 Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 05.02.22

- [Biologics, Proteins, Vaccines](#)
Advanced Therapy Manufacturing
 Flexible facility design for multi-product manufacturing of advanced therapies: An end user perspective.
 Emily Moran, Vice President, Vector Manufacturing The Center for Breakthrough Medicines 05.02.22

- Advanced Therapy Packaging Trends**
 Successful processing of advanced therapy medicinal products requires careful planning, experimentation and validation, tight controls and extreme caution.
 Mark English, Vice President of Packaging & Logistics Operations Almac Pharma Services 05.02.22

A large advertisement for August Bioservices. The background is a grayscale image of a pharmaceutical manufacturing facility. On the left, a woman wearing a hairnet and safety glasses smiles. In the center, there are large stainless steel industrial tanks and piping. On the right, a conveyor belt carries several glass vials. The August Bioservices logo, consisting of the word 'august' in lowercase purple letters and 'bioservices' in smaller lowercase blue letters, is positioned in the center. To the right of the text is a stylized purple and blue logo element. A purple banner at the bottom of the advertisement contains the following text:

Sterile Injectables CDMO
US-Based • End-to-End • All Under One Roof
2023/2024 capacity available!



Suggested Reading

- [HPNE Launches Innovative Single-Use Assembly Service](#)
- [Catalent Bolsters Cell and Gene Services](#)
- [Enhancing Ease of Use, Batch Turnaround, and Process Flexibility](#)
- [Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security](#)
- [Beat the Supply Chain Backlog](#)

Trending

- [Catalent Opens Manufacturing Facility For Cell Therapies](#)
- [Andelyn Biosciences, Odyliia Therapeutics Partner To Manufacture Gene Therapy For Vision Loss](#)
- [Lonza Breaks Ground On Commercial Drug Product Facility In Stein](#)
- [Lilly To Invest \\$450M At Manufacturing Site In Research Triangle Park](#)
- [Seqens Opens Flagship R&D Center In Greater Boston](#)

Breaking News

- [Steriline Provides Fill-Finish Solution for Berkshire Sterile Manufacturing](#)
- [Bionova Expansion Project to Quadruple GMP Biologics Manufacturing Capacity](#)
- [Merck Revenues up 22% for the Year to \\$59.3B](#)
- [BioNTech SE Completes Plasmid DNA Manufacturing Facility in Marburg, Germany](#)
- [Dragonfly Therapeutics Appoints Joseph Eid as President of Research & Development](#)

[View Breaking News >](#)

CURRENT ISSUE

[January/February 2023](#)

[View More >](#)

CONTRACT PHARMA | WEBINARS

Biosynthesis of Chiral Compounds at Hiray Pharma Solutions

Thursday, February 16 | 10:00 AM ET

Sponsored by 汉瑞药业
Hiray Pharma

CONTRACT PHARMA WEBINAR

CDMO Selection and Tech Transfer – An Insider’s Guide to Injectables Excellence

March 2, 2023 | 11AM ET

Sponsored by august

- [About Us](#)
- [Privacy Policy](#)
- [Terms And Conditions](#)
- [Contact Us](#)

follow us

-
-
-
-

Nutraceuticals World

[Latest Breaking News From Nutraceuticals World](#)

[GOED Elects New Board Officers for 2023](#)

[Aspire Hires Darrec Jones as VP of Business Development](#)

[Pycnogenol Supplementation Linked to Better Hair Density in Menopausal Women](#)

COATINGS WORLD

[Latest Breaking News From Coatings World](#)

[PPG Completes COLORFUL COMMUNITIES Project in Denmark](#)

[10 Partners of the Automotive Industry Form JV, Cofinity-X](#)

[BASE Recognized as Top Company for Supplier Diversity](#)

Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

- [Latest Breaking News From Medical Product Outsourcing](#)
- [Chiral Bioscience's New Process Improves Outcomes in Heart Transplantation](#)
- [FDA Approves Boston Scientific's LithoVue Elite Single-Use Digital Flexible Ureteroscope](#)
- [New View Surgical Closes \\$12.1M Series B-1 Financing](#)

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

- [Latest Breaking News From Contract Pharma](#)
- [Bionova Expands Single-Use Disposable GMP Manufacturing Capacity](#)
- [Steriline Provides Fill-Finish Solution for Berkshire Sterile Manufacturing](#)
- [Merck Revenues up 22% for the Year to \\$59.3B](#)

- [Latest Breaking News From Beauty Packaging](#)
- [Lush Supports Cancer Research with New Bath Bomb](#)
- [e.l.f. Beauty Net Sales Grow 49% in Third Quarter of 2023](#)
- [DOVE Introduces 'Next-Gen' Body Wash in Sleek New Sustainable Bottle](#)

Latest Breaking News From Happi

[Paco Rabanne Dies at 88](#)

[Kering Creates New Beauty Unit for Bottega Veneta, Balenciaga, Alexander McQueen, Pomellato & Qeelin](#)

[Gojo Patents Hand Sanitizer with Probiotics/Prebiotics](#)



Latest Breaking News From Ink World

[Roland DGA Announces Key Changes to Leadership Team](#)

[Ball Reports 2022 Results](#)

[3D Printing Materials Market Worth \\$7.9 Billion by 2027: MarketsandMarkets](#)



Latest Breaking News From Label & Narrow Web

[Cepi, EHPA partner for energy savings in paper manufacturing](#)

[Brook + Whittle acquires LLT Labels](#)

[ABG adds laser perforation to shrink sleeve seaming solution](#)

Latest Breaking News From Nonwovens Industry

[Qvin Menstrual Blood Diagnostic Device Receives FDA Approval in Thailand](#)

[Andritz, KCF Technologies Form Agreement](#)

[Freudenberg e-Power Systems, LG Energy Solution Announce Partnership](#)



Latest Breaking News From Orthopedic Design & Technology

[Toetal Solutions Secures \\$1.8 Million in New Financing](#)

[Adrian Tyndall Joins Axogen's Board of Directors](#)

[ADSM-Synchro Medical Acquired by Tyber Medical](#)



Latest Breaking News From Printed Electronics Now

[Zebra Provides East West Shrine Bowl with RFID Tracking Technology](#)

[AAAS Elects Three ORNL Scientists as Fellows](#)

[Flex Recognized as One of Fortune World's Most Admired Companies 2023](#)